HepC is developing an antiviral agent that might be used against several acute and chronic virus infections. The basic concept of this technology platform is a revolutionary idea, using an entirely different modality from antiviral drugs currently in pipelines. It is achieved via viral superinfection therapy (SIT) using a non-pathogenic attenuated Infectious Bursal Disease Virus (IBDV), which is a double-stranded RNA (ds RNA) virus that induces high levels of TH1 / interferon responses. The agent can be orally administered as it is both temperature and pH stable and not considered to be a zoonotic hazard.
HepC has an intellectual property portfolio that includes issued and allowed US and EU patents serving as the foundation for the development of its virus based medicines. More specifically, HepC has an issued US patent on the composition of matter of a novel apathogenic viral strain R903/78. This preferred viral strain of IBDV is specifically characterized in terms of structure and biological activities.
HepC also has allowed patents in EU for the IBDV technology and related treatment of viral hepatitis. Furthermore, the invention also provides claims to treat all other viral infections not related to viral hepatitis.